Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
19:40:09 EDT Sat 18 May 2024
Enter Symbol
or Name
USA
CA



News for U:BPMC from 2023-05-18 to 2024-05-17 - 32 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-06 16:01U:BPMCNews ReleaseBlueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-05-02 07:00U:BPMCNews ReleaseBlueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT(TM)/AYVAKYT(TM) (avapritinib) Full Year Revenue Guidance
2024-04-18 08:00U:BPMCNews ReleaseBlueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
2024-04-11 08:00U:BPMCNews ReleaseBlueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics
2024-04-04 16:01U:BPMCNews ReleaseBlueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-06 16:01U:BPMCNews ReleaseBlueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-23 08:00U:BPMCNews ReleaseBlueprint Medicines Highlights AYVAKIT(TM) (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting
2024-02-15 07:00U:BPMCNews ReleaseBlueprint Medicines Reports Fourth Quarter and Full Year 2023 Results
2024-02-05 16:01U:BPMCNews ReleaseBlueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-01 08:00U:BPMCNews ReleaseBlueprint Medicines to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024
2024-01-08 08:00U:BPMCNews ReleaseBlueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference
2024-01-05 16:01U:BPMCNews ReleaseBlueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-12-18 08:00U:BPMCNews ReleaseBlueprint Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference
2023-12-12 08:05U:BPMCNews ReleaseBlueprint Medicines' AYVAKYT ‚ ® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis
2023-12-09 12:30U:BPMCNews ReleaseBlueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted at 2023 ASH Annual Meeting
2023-12-04 16:01U:BPMCNews ReleaseBlueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-28 08:00U:BPMCNews ReleaseBlueprint Medicines to Present at JMP Securities Hematology and Oncology Summit
2023-11-10 08:00U:BPMCNews ReleaseBlueprint Medicines' AYVAKYT ‚ ® (avapritinib) Receives Positive CHMP Opinion as the First and Only Therapy for Indolent Systemic Mastocytosis
2023-11-03 16:01U:BPMCNews ReleaseBlueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-10-26 07:00U:BPMCNews ReleaseBlueprint Medicines Reports Third Quarter 2023 Results
2023-10-23 08:30U:BPMCNews ReleaseAnixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board
2023-10-12 08:00U:BPMCNews ReleaseBlueprint Medicines to Report Third Quarter 2023 Financial Results on Thursday, October 26, 2023
2023-10-05 16:01U:BPMCNews ReleaseBlueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-05 16:01U:BPMCNews ReleaseBlueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-08-04 16:16U:BPMCNews ReleaseBlueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-08-02 07:00U:BPMCNews ReleaseBlueprint Medicines Reports Second Quarter 2023 Results
2023-07-19 08:00U:BPMCNews ReleaseBlueprint Medicines to Report Second Quarter 2023 Financial Results on Wednesday, August 2, 2023
2023-07-05 16:30U:BPMCNews ReleaseBlueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-06-05 17:00U:BPMCNews ReleaseBlueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-06-03 09:00U:BPMCNews ReleaseBlueprint Medicines Highlights Clinical Progress Across Precision Oncology Pipeline at 2023 ASCO Annual Meeting
2023-05-23 10:00U:BPMCNews ReleaseNEJM Evidence Publishes Results from Registrational PIONEER Trial Demonstrating Significant Clinical Benefits of AYVAKIT ‚ ® (avapritinib) in Patients with Indolent Systemic Mastocytosis
2023-05-22 16:04U:BPMCNews ReleaseFDA Approves AYVAKIT ‚ ® (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis